In8bio (INAB): which funds own it

Who owns In8bio?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Lytton Laurence W, 10.0% (13G/A filed Aug 13, 2026), Alyeska Investment Group, 9.9% (13G filed Feb 17, 2026), Stonepine Capital Management, 9.9% (13G filed Dec 22, 2025), Franklin Resources, 9.4% (13G filed Jan 29, 2026) and 683 Capital Management, 7.9% (13G filed Dec 30, 2025). As of Jun 30, 2026, the largest holders reported on Form 13F were Alyeska Investment Group (9.6% of the shares), Franklin Resources (9.3%) and 683 Capital Management (7.4%).

Sources:13G/A by Lytton Laurence W (Aug 13, 2026) ↗13G by Alyeska Investment Group (Feb 17, 2026) ↗13G by Stonepine Capital Management (Dec 22, 2025) ↗13G by Franklin Resources (Jan 29, 2026) ↗13G by 683 Capital Management (Dec 30, 2025) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 4, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• Alyeska Investment Group944 KInvestment firm · 9.58% of the company0
• Franklin Resources915 KInvestment firm · 9.28% of the company0
• 683 Capital Management725 KType not verified · 7.35% of the company0
• Stonepine Capital Management695 KInvestment firm · 7.05% of the company+32 K
• Vanguard Capital Management89 KIndex manager · 0.90% of the company0
• BIOS Capital Management81 KType not verified · 0.82% of the company−87 K
• Geode Capital Management73 KIndex manager · 0.74% of the company−14 K
• Citadel Advisors63 KQuant or multi-manager · 0.64% of the company+63 K
• Oppenheimer63 KType not verified · 0.64% of the company+39 K
• Vanguard Fiduciary Trust44 KIndex manager · 0.44% of the company0

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 38.5% of the shares · top 10: 37.5% · in index firms: 6.0% of the institutional total

Shares reported by the 21 13F filers as of Jun 30, 2026 (not counting 1 position with implausible figures), divided by the shares outstanding on the cover of the company's latest report (May 4, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• May 7, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Feb 27, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Feb 9, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Dec 19, 2025Routinefiling ↗

  Unregistered sale of equity securities (Item 3.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.